Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (51-60 of 157) with videos related to

Pageof 16
Sort By:
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Patient Preference and Adherence|December 14, 2011
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector devicePeter Varunok, Eric Lawitz, Kimberly L Beavers, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Health Science Reports|April 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT studyEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Journal of Hepatology|February 27, 2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentEric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 3, 2026
A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosisMaria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Clinical Pharmacokinetics|March 10, 2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic ImpairmentErik Mogalian, Diana M Brainard, Anu Osinusi, et al.
The Journal of Infection|September 24, 2014
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionEric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, et al.
Pageof 16

Showing results (51-60 of 157) with videos related to

Sort By:
Pageof 16
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Patient Preference and Adherence|December 14, 2011
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector devicePeter Varunok, Eric Lawitz, Kimberly L Beavers, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Health Science Reports|April 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT studyEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Journal of Hepatology|February 27, 2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentEric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 3, 2026
A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosisMaria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Clinical Pharmacokinetics|March 10, 2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic ImpairmentErik Mogalian, Diana M Brainard, Anu Osinusi, et al.
The Journal of Infection|September 24, 2014
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionEric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, et al.
Pageof 16